(Image Credit: AdobeStock) Apotex Corp. has released its latest ophthalmic product in the United States, brimonidine tartrate ophthalmic solution, 0.1%, which is now available.
Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. 1
(Image Courtesy: Apotex Corp.) “Open-angle glaucoma impacts over 2.7 million Americans, and millions more have ocular hypertension. Bringing this product to market will make a real difference for these patients, who depend on this medicine to preserve their vision,” said Peter Hardwick, President, Apotex Corp. “We’re excited to be able to […]
Click here to visit source. www.ophthalmologytimes.com